Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutch national observational monitoring study of the new atypical hemolytic uremic syndrome treatment guideline
NL-OMON44007Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of eculizumab, sponsored by Radboud University Medical Center. Planned start Aug 2016; status: not yet recruiting.
02
Drugs
eculizumab
Beyond the preview
Go deeper on NL-OMON44007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44007.